2023-11-13T16:20:53-06:00 2022-12-31 521446779 JOHNSON LAMBERT LLP 4242 SIX FORKS ROAD SUITE 1500 RALEIGH NC 27609 990 2022-01-01 030466352 THE GOG FOUNDATION INC GOGF 4107217126 3168 BRAVERTON ST 280 EDGEWATER MD 21037 MARY C SHARP CHIEF FINANCIAL OFFICER 4107217126 2023-11-13 1 MARY SHARP XXX-XX-XXXX 0 J CALVIN MARKS P01226973 9197196400 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z LARRY J COPELAND MD 3168 BRAVERTON ST 280 EDGEWATER MD 21037 115378112 0 X WWW.GOG.ORG X 2002 DC THE GOG FOUNDATION'S PRIMARY EXEMPT PURPOSE IS TO PROMOTE EXCELLENCE IN THE QUALITY AND INTEGRITY OF CLINICAL AND BASIC SCIENTIFIC RESEARCH IN THE FIELD OF GYNECOLOGIC MALIGNANCIES. 16 6 59 0 54836 42782 2532775 2549203 62113804 73957493 6285565 2361707 139537 95112 71071681 78963515 240000 208508 0 0 7098442 7944266 0 0 364475 53320348 69723408 60658790 77876182 10412891 1087333 118907888 121695813 28813492 43238359 90094396 78457454 X THE GOG FOUNDATION, INC. (GOG FOUNDATION) IS A NONPROFIT ORGANIZATION WITH THE PURPOSE OF PROMOTING EXCELLENCE IN THE QUALITY AND INTEGRITY OF CLINICAL AND BASIC SCIENTIFIC RESEARCH IN THE FIELD OF GYNECOLOGIC MALIGNANCIES, INCLUDING CANCERS THAT ARISE FROM THE OVARIES, UTERUS, CERVIX, VAGINA, AND VULVA. OUR INSTITUTIONS AND INVESTIGATORS ARE ESSENTIAL CONTRIBUTORS TO ADVANCEMENTS IN TREATMENT REGIMENS, SURGICAL PROCEDURES, QUALITY OF LIFE ANALYSES, AND PREVENTION KNOWLEDGE. THE RESULTS OF GOG FOUNDATION CLINICAL TRIALS HAVE INFLUENCED THE STANDARD OF CARE FOR NUMEROUS MALIGNANT GYNECOLOGIC NEOPLASMS. THE MISSION OF THE GOG FOUNDATION IS TO CONDUCT CLINICAL AND TRANSLATIONAL RESEARCH THAT POSITIVELY IMPACTS WOMEN THROUGH THE PREVENTION AND TREATMENT OF GYNECOLOGIC MALIGNANCIES. THE VISION OF THE GOG FOUNDATION IS TO BE THE PREMIER COLLABORATIVE NETWORK FOR TRANSFORMATIVE RESEARCH IN GYNECOLOGIC MALIGNANCIES. 0 0 77145854 208508 73957493 THE FOUNDATION IS COMMITTED TO MAINTAINING THE HIGHEST STANDARDS IN CLINICAL TRIALS DEVELOPMENT, EXECUTION, ANALYSIS AND DISTRIBUTION OF RESULTS. CONTINUOUS EVALUATION OF OUR PROCESSES IS UTILIZED IN ORDER TO CONSTANTLY IMPROVE THE QUALITY OF PATIENT CARE. IN 2022 THE GOG FOUNDATION, INC. CONDUCTED CLINICAL TRIALS THROUGH OUR 300 PLUS INSTITUTIONS. THESE EXPENSES INCLUDED PROTOCOL DEVELOPMENT, REGULATORY AFFAIRS, MEETINGS TO REVIEW TRIAL DATA, TRIAL DEVELOPMENT THROUGH COMMITTEE FUNCTIONS AND OTHER INDIRECT RELATED EXPENSES. 77145854 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 1 156 0 1 59 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 16 6 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 MD X MARY C SHARP CFO 4107217126 3168 BRAVERTON ST NO 280 EDGEWATER MD 21037 MARY SHARP CHIEF FINANCIAL OFFICER 35.00 X 301177 0 63465 MICHAEL S POWERS GENERAL COUNSEL 35.00 X 286879 0 45031 LAURA L REESE EXECUTIVE DIRECTOR, OPERATIONS 35.00 X 268254 0 61477 JENNIFER T KIEN EXECUTIVE DIRECTOR OF BUSINESS DEVELOPMENT 35.00 X 237185 0 65071 KATHLEEN E CAMPBELL-SIMMS EXECUTIVE DIRECTOR, CLINICAL TRIALS MANAGEMENT 35.00 X 160766 0 56917 NOLA R BENCZE COMPLIANCE ATTORNEY 35.00 X 161787 0 46498 NICOLE M LAMACK SR. DIR, GRANTS, ACCOUNTING & SITE CONTRACTING 35.00 X 162333 0 42563 HEATHER LANKES DIRECTOR, TRANSLATIONAL RESEARCH 35.00 X 159495 0 41449 JOSH J KILLION DIRECTOR, INFORMATION TECHNOLOGY 35.00 X 163427 0 33579 WENDY WELLS DIRECTOR OF FINANCE 35.00 X 159254 0 27546 LARRY J COPELAND MD PRESIDENT 20.00 X X 100000 0 0 ROBERT S MANNEL MD SR. VICE PRESIDENT 13.00 X X 33000 0 0 THOMAS J HERZOG MD TREASURER 1.00 X X 0 0 0 DAVID G MUTCH MD SECRETARY 1.00 X X 0 0 0 CAROL AGHAJANIAN MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 ROBERT L COLEMAN MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 PAUL A DISILVESTRO MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 BRADLEY J MONK MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 KATHLEEN N MOORE MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 TASHANNA MYERS MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 ALEXANDER B OLAWAIYE MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 DAVID O'MALLEY MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 LESLIE M RANDALL MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 ANGELES ALVAREZ SECORD MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 BRIAN SLOMOVITZ MD DIRECTOR-AT-LARGE 1.00 X 0 0 0 SHANNON WESTIN MD DIRECTOR-AT-LARGE (FROM JUN '22) 1.00 X 0 0 0 2193557 0 483596 17 0 1 0 DR THOMAS J HERZOG MD 231 ALBERT SABIN WAY CINCINNATI OH 45267 CONSULTING SERVICES 293188 DR ROBERT COLEMAN MD 9180 PINECROFT DR STE 600 THE WOODLANDS TX 77380 CONSULTING SERVICES 266000 UNIVERSITY CANCER ASSOCIATES INC 3626 N MOHAVE WAY SCOTTSDALE AZ 85251 CONSULTING SERVICES 259740 DR LARRY J COPELAND MD 3691 RIDGE MILL DR HILLIARD OH 43026 CONSULTING SERVICES 225875 DR DAVID O'MALLEY MD 3651 RIDGE MILL DR HILLIARD OH 43026 CONSULTING SERVICES 133260 9 2124637 424566 2549203 INDUSTRY REVENUE 900099 73913976 73913976 REGISTRATION FEES 900099 43517 43517 73957493 2293359 54836 2238523 36482945 36414597 68348 68348 68348 95112 95112 95112 78963515 73957493 54836 2401983 208508 208508 1679223 993443 638660 47120 4467887 2639572 1733671 94644 624073 322623 284041 17409 772906 385975 270328 116603 400177 240183 148918 11076 784130 740194 43936 61623 61623 2265410 1777732 487678 1327 1327 237449 77187 159050 1212 217680 39675 178005 941001 250381 690620 633648 558732 49423 25493 827645 723795 94278 9572 421619 421619 PURCHASE SERVICE AGREEM 58658754 58658754 CONSORTIUMS 3251432 3251432 HONORARIA 1202575 1202575 OVERHEAD ALLOCATION 0 5026244 -5026244 219115 48849 128920 41346 77876182 77145854 365853 364475 961 2481 28395062 38407310 388266 468851 5504189 9653960 43068 0 78072847 59122593 5466267 10432436 985449 1011933 51779 2596249 118907888 121695813 9120248 7264116 19693244 32864800 0 3109443 28813492 43238359 X 90094396 78457454 90094396 78457454 118907888 121695813 1087333 -12724275 0 X 0 1 X 1 1 1 X 3475111 2990743 3264417 2532775 2549203 14812249 3475111 2990743 3264417 2532775 2549203 14812249 14812249 1558710 2026706 2080100 2322219 2238523 10226258 115076 21845 17268 42782 196971 23997 48680 4954 139537 95112 312280 25547758 250828254 0.57980 0.63770 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 ALTERNATIVE INVESTMENTS 10432436 C 10432436 LEASE LIABILITIES - OPERATING LEASES 3109443 3109443 X 66239240 -12724275 -12724275 78963515 0 78963515 77876182 0 77876182 0 77876182 PART X, LINE 2: MANAGEMENT HAS CONCLUDED THAT GOG FOUNDATION HAS PROPERLY MAINTAINED ITS EXEMPT STATUS, AND THERE ARE NO UNCERTAIN TAX POSITIONS AS OF DECEMBER 31, 2022 OR 2021. CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 3566000 0 0 0 0 0 0 3566000 0 3566000 0 0 0 0 1 0 PART III ACCOUNTING METHOD: 1 CURATORS OF THE UNIVERSITY OF MISSOURI SPECIAL TR 407 REYNOLDS ALUMNI CTR COLUMBIA MO 65211 266440629 501(C)(3) 150000 0 GENERAL PURPOSE GRANT AMERICAN ASSOCIATION OF OBSTETRICIANS & GYN FOUNDATION 2331 ROCK SPRING RD FOREST HILL MD 21050 386042799 501(C)(3) 45758 0 GENERAL PURPOSE GRANT SOCIETY OF GYNECOLOGIC ONCOLOGY 230 W MONROE ST STE 170 CHICAGO IL 60606 611657046 501(C)(6) 12750 0 SGO FLY IN DAY 2 1 PART I, LINE 2: THE GOG FOUNDATION SELECTS ORGANIZATIONS FOR GRANTS THAT FURTHER THE EXEMPT PURPOSE OF THE GOG FOUNDATION. THE RECIPIENTS OF THESE GRANTS ARE EXEMPT ORGANIZATIONS WITH MISSIONS CONGRUOUS WITH THOSE OF THE GOG FOUNDATION. X X 0 0 0 0 0 0 0 0 0 MARY SHARP CHIEF FINANCIAL OFFICER 288822 0 1500 0 10855 0 45672 0 17793 0 364642 0 0 0 MICHAEL S POWERS GENERAL COUNSEL 275093 0 1500 0 10286 0 43280 0 1751 0 331910 0 0 0 LAURA L REESE EXECUTIVE DIRECTOR, OPERATIONS 255554 0 1984 0 10716 0 40847 0 20630 0 329731 0 0 0 JENNIFER T KIEN EXECUTIVE DIRECTOR OF BUSINESS DEVEL 226939 0 1625 0 8621 0 36299 0 28772 0 302256 0 0 0 KATHLEEN E CAMPBELL-SIMMS EXECUTIVE DIRECTOR, CLINICAL TRIALS 151879 0 2216 0 6671 0 24972 0 31945 0 217683 0 0 0 NOLA R BENCZE COMPLIANCE ATTORNEY 151171 0 3866 0 6750 0 25231 0 21267 0 208285 0 0 0 NICOLE M LAMACK SR. DIR, GRANTS, ACCOUNTING & SITE C 154162 0 1500 0 6671 0 24864 0 17699 0 204896 0 0 0 HEATHER LANKES DIRECTOR, TRANSLATIONAL RESEARCH 151448 0 1500 0 6547 0 24402 0 17047 0 200944 0 0 0 JOSH J KILLION DIRECTOR, INFORMATION TECHNOLOGY 155256 0 1500 0 6671 0 24864 0 8715 0 197006 0 0 0 WENDY WELLS DIRECTOR OF FINANCE 152737 0 0 0 6517 0 24291 0 3255 0 186800 0 0 0 DR THOMAS J HERZOG MD TREASURER 293188 CONSULTING SERVICES 0 DR ROBERT L COLEMAN MD DIRECTOR-AT-LARGE 266000 CONSULTING SERVICES 0 DR BRADLEY J MONK MD DIRECTOR-AT-LARGE 259740 CONSULTING, PROVIDED BY BUSINESS OWNED BY DIRECTOR 0 DR LARRY J COPELAND MD PRESIDENT 225875 CONSULTING SERVICES 0 DR ROBERT S MANNEL MD SR. VICE PRESIDENT 159227 CONSULTING SERVICES, PAID TO DIRECTOR'S EMPLOYER 0 DR DAVID O'MALLEY MD DIRECTOR-AT-LARGE 133260 CONSULTING SERVICES 0 DR BRADLEY J MONK MD DIRECTOR-AT-LARGE 119790 CONSULTING SERVICES 0 DR BRIAN SLOMOVITZ MD DIRECTOR-AT-LARGE 106900 CONSULTING SERVICES 0 DR LESLIE M RANDALL MD DIRECTOR-AT-LARGE 105625 CONSULTING SERVICES 0 DR KATHLEEN N MOORE MD DIRECTOR-AT-LARGE 86260 CONSULTING SERVICES, PAID TO DIRECTOR'S EMPLOYER 0 MS NICOLE COPELAND FAMILY MEMBER OF PRESIDENT 75599 CONSULTING SERVICES 0 DR ANGELES ALVAREZ SECORD MD DIRECTOR-AT-LARGE 31000 CONSULTING SERVICES 0 DR SHANNON WESTIN MD DIRECTOR-AT-LARGE 12650 CONSULTING SERVICES 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE CFO BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED ANNUALLY BY THE FOUNDATION CHAIR, AND ON AN INTERIM BASIS. THE FOUNDATION CHAIR REVIEWS ANNUAL FORMS NO LATER THAN NOVEMBER 1 OF EACH YEAR, AND INTERIM FORMS WITHIN 30 DAYS. THE CONFLICT IS MANAGED, REDUCED, OR ELIMINATED, AT LEAST ON AN INTERIM BASIS, WITHIN 60 DAYS OF ITS IDENTIFICATION. FORM 990, PART VI, SECTION B, LINE 15 OFFICER AND KEY EMPLOYEE SALARY IS APPROVED BY THE CEO AND TREASURER ANNUALLY, IN CONSULTATION WITH A COMPENSATION SURVEY WHICH IS OBTAINED PERIODICALLY. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, POLICIES, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AT RECEPTIONIST'S DESK. FORM 990, PART VII, SECTION A: DR. MANNEL'S EMPLOYER, THE UNIVERSITY OF OKLAHOMA, WAS COMPENSATED $33,000 FOR DR. MANNEL'S SERVICES TO THE BOARD.